Posts Tagged ‘long-acting muscarinic antagonists’

May 20th, 2013

Similar Cardiovascular Risk Observed with COPD Drugs

A large observational study has found no difference in the increased risk for cardiovascular disease between the two main classes of drugs used in the first-line treatment of chronic obstructive pulmonary disease (COPD). LABAs (long-acting inhaled beta-agonists) and LAMAs (long-acting muscarinic antagonists) have a variety of beneficial effects in COPD patients, but evidence has been […]